Academic Journals Database
Disseminating quality controlled scientific knowledge

EFFECTIVENESS OF I AND II LINE CHEMO-TARGETED THERAPY ACCORDING TO THE SCHEME OXALIPLATIN +CAPECITABINE + BEVACIZUMAB (XELOX+BEV) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)

ADD TO MY LIST
 
Author(s): KALDYGUL SMAGULOVA | NINO CHICHUA | ZHETKERGEN ARZYKULOV | SURIYA YESENTAYEVA | RAMIL ABDRAKHMANOV | ASSEL TUMANOVA | SHOLPAN MUKANOVA | AICHA МOLDASHEVA

Journal: Medical and Health Science Journal
ISSN 1804-1884

Volume: 8;
Issue: 4;
Start page: 6;
Date: 2011;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: Colorectal cancer | liver metastases | chemo-targeted treatment | vascular endothelial growth factor (VEGF)

ABSTRACT
The research involved 38 mCRC patients, aged 23-73 (medium age -55 years). Patients with mCRC were randomized into two groups. This mode of chemo-targeted therapy was conducted in the first group (20 patents) in a second line, since these patients previously were treated by the chemotherapy schemes FOLFIRIor FOLFOX. Patients were treated in the mode: Capecitabine in 2000mg/m2 2 times a day from the 1st to the 14th day, 2-hour infusion of capsular Oxaliplatin 130mg/m2, day 1, Bevacizumab 5mg/kg 1 time per 14 days. The overall objective effect was obtained in 15 patients (39.5±7.9) %: in group 1 - in 7 patients (35.0 + 10.6%), in the 2group - 8 cases (44.4±11.7%), of which complete regression - in 1 (5%) and 2 (11.1%) cases, respectively. In 30% of cases the partial response and a greater number of stabilization (50% and 44.5% respectively) were reported. Progression of the process was observed at 15% in a group 1 and 11.1% of cases in group 2. Terms of remission were group 1 - 8.2 months, group 2 - 12.1 months. Thus, XELOX + BEV shows the sufficient efficacy in patients with mCRC, both in I and II lines of chemotherapy, with an acceptable toxicity profile.
RPA Switzerland

Robotic Process Automation Switzerland

    

Tango Jona
Tangokurs Rapperswil-Jona